| abstract |
Use of a pyrido[3',2':4,5]thieno[3,2-d]pyrimidine derivative of formula (I), wherein n is an integer selected from 0 or 1 R1 and R2 are independently selected from hydrogen atoms and C1-4 alkyl groups R3 represents a group selected from alkyl, amino, monoalkylamino, dialkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups bound through the nitrogen atom to the piridine ring, all of them being optionally substituted by one or more substituents selected from the group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, R6000-, alkoxy, R6R7N-CO-, -CN, -CF3, -NR6R7, -SR6 and - SO2NH2 groups wherein R6 and R7 are independently selected from hydrogen atoms and C1-4 alkyl groups R4 and R5 are independently selected from the group consisting of hydrogen atoms, alkyl groups and groups of formula (II): wherein p and q are integers selected from 1, 2 and 3; A is either a direct bond or a group selected from -CONR12-, -NR12CO-, -O-, -COO-, -OCO-, -NR12COO-, -OCONR12-, -NR12CONR13-, -S-, -SO-, -SO2-, -COS- and -SCO-; and G2 is a group selected from aryl, heteroaryl or heterocyclyl; wherein the alkyl groups and the group G2 are optionally substituted by one or more substuents selected from group consisting of halogen atoms and alkyl, alkoxyalkyl, arylalkyl, R14OCO-, hydroxy, alkoxy, oxo, R14R15N-CO-, -CN, -CF3, -NR14R15, -SR14 and -SO2NH2 groups; wherein the groups R8 to R15 are independently selected from hydrogen atoms and C1_4 alkyl groups; and the pharmaceutically acceptable salts and N-oxides thereof; in the manufacture of a medicament for the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of phosphodiesterase 4. |